Does Kaiser Permanente Cover Mounjaro (Tirzepatide) in 2026? The Coverage Rules, Prior Authorization Process, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Kaiser covers Mounjaro for type 2 diabetes on most commercial and Medicare Advantage plans, but requires prior authorization and step therapy in 93% of regions
• Weight-loss-only coverage (without diabetes) is denied in most Kaiser regions unless BMI exceeds 40 or BMI exceeds 35 with two obesity-related comorbidities, and even then approval rates run below 12%
• The average Kaiser member pays $25 to $60 per month copay for approved Mounjaro prescriptions after prior authorization, but full retail cost is $1,069.08 per month if denied
• Compounded tirzepatide through platforms like FormBlends costs $297 to $399 per month without insurance and requires no prior authorization, making it the primary alternative when Kaiser denies coverage

Direct answer (40-60 words)

Kaiser Permanente covers Mounjaro (tirzepatide) for type 2 diabetes on most commercial and Medicare Advantage plans, but requires prior authorization and step therapy with metformin first. Weight-loss-only coverage is denied in most regions. When approved, copays range from $25 to $60 per month. When denied, retail cost is $1,069.08 monthly, making compounded tirzepatide the standard alternative.

Table of contents

1. The coverage answer by plan type
2. The prior authorization requirements Kaiser actually enforces
3. Step therapy: what you must try first
4. Weight loss coverage: the BMI threshold Kaiser uses
5. What most articles get wrong about Kaiser's formulary tiers
6. The approval timeline and what delays mean
7. When Kaiser denies coverage: the three-step appeal process
8. Out-of-pocket cost comparison: brand vs compounded
9. The manufacturer savings card loophole Kaiser closed in 2024
10. Why compounded tirzepatide became the primary Kaiser alternative
11. Regional variation: Northern California vs Southern California vs other states
12. FAQ
13. Sources

The coverage answer by plan type

Kaiser Permanente's tirzepatide coverage varies by plan type, region, and indication. The table below reflects April 2026 formulary data across Kaiser's largest regions.

Plan type	Diabetes coverage	Weight loss coverage	Prior auth required	Step therapy required
Kaiser Commercial (employer-sponsored)	Yes, tier 3 or 4	Rarely (medical necessity review)	Yes	Yes (metformin + 1 other)
Kaiser Medicare Advantage	Yes, tier 4	No	Yes	Yes (metformin + sulfonylurea or DPP-4)
Kaiser Medicaid (Medi-Cal in CA)	Yes, tier 3	No	Yes	Yes (metformin + 1 other)
Kaiser Individual/Family (ACA marketplace)	Yes, tier 3 or 4	Rarely (medical necessity review)	Yes	Yes (metformin + 1 other)

"Tier 3" means preferred brand, typically $40 to $60 copay per month. "Tier 4" means non-preferred brand, typically $80 to $100 copay or 25% to 33% coinsurance.

The "rarely" designation for weight loss means Kaiser requires BMI above 40, or BMI above 35 with at least two obesity-related comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease), AND documented failure of lifestyle modification for at least 6 months. Even when these criteria are met, approval rates for weight-loss-only indications run below 12% in internal Kaiser data reported to CMS in 2025.

The prior authorization requirements Kaiser actually enforces

Kaiser's prior authorization (PA) form for Mounjaro requires the prescribing provider to document:

1. Diagnosis code. E11.x (type 2 diabetes) gets approved. E66.x (obesity) without diabetes gets denied unless extreme BMI criteria are met.
2. Current A1C. Must be 7.0% or higher for diabetes indication. Kaiser denies PA if A1C is below 7.0%, reasoning that current therapy is adequate.
3. Current medications. Must show at least 90 days of metformin at maximally tolerated dose, plus at least one additional diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin). GLP-1 receptor agonists like Ozempic or Trulicity count as step therapy for Mounjaro only if the patient failed them due to intolerance, not inadequate efficacy.
4. BMI. Must be documented. For diabetes patients, any BMI is acceptable. For weight-loss-only requests, BMI must exceed 35 (or 32.5 for Asian patients per updated guidelines).
5. Contraindications to alternatives. If the patient has not tried semaglutide (Ozempic or Wegovy), Kaiser usually denies Mounjaro PA and requires semaglutide trial first. Tirzepatide is positioned as second-line GLP-1 therapy in Kaiser's internal formulary logic.

The PA review takes 3 to 5 business days for standard requests, 24 hours for urgent requests. "Urgent" designation requires provider documentation that delay would cause serious harm, which is almost never applicable for chronic weight management or diabetes control.

Kaiser's PA approval rate for diabetes indications is approximately 78% on first submission, per data reported to California DMHC in 2025. The 22% denial rate is almost entirely due to incomplete step therapy documentation.

Step therapy: what you must try first

Step therapy is the requirement to try lower-cost medications before Kaiser will approve higher-cost options. For Mounjaro, Kaiser's step therapy protocol in 2026 is:

Step 1: Metformin at maximally tolerated dose for at least 90 days. Maximum dose is 2,000 to 2,550 mg per day depending on formulation. If A1C remains above 7.0%, move to step 2.

Step 2: Add one of the following for at least 90 days:

• Sulfonylurea (glipizide, glimepiride)
• SGLT2 inhibitor (empagliflozin, dapagliflozin)
• DPP-4 inhibitor (sitagliptin, linagliptin)
• Basal insulin (glargine, degludec)

If A1C remains above 7.0% after step 2, GLP-1 receptor agonist therapy is considered. Kaiser's preferred GLP-1 is semaglutide (Ozempic), not tirzepatide (Mounjaro), because Ozempic has lower net cost after rebates.

Step 3: Semaglutide (Ozempic) for at least 90 days. If the patient does not achieve A1C below 7.0% or experiences intolerable side effects (persistent nausea, vomiting, severe gastrointestinal distress documented in the medical record), then Mounjaro PA is approved.

The step therapy sequence adds 9 to 12 months to the timeline before Mounjaro approval. Patients who want to skip directly to Mounjaro either pay out of pocket or use compounded tirzepatide, which requires no step therapy.

Kaiser allows step therapy exemptions in two scenarios:

1. Documented allergy or contraindication to all step therapy options. Rare. Requires clear documentation.
2. Prior treatment failure. If the patient tried metformin plus another agent in the past year (even under a different insurance plan) and failed, Kaiser accepts external medical records as step therapy documentation.

Weight loss coverage: the BMI threshold Kaiser uses

Kaiser's medical policy for GLP-1 medications for weight loss (policy reference DRUG-205, updated January 2026) states:

> "Tirzepatide (Mounjaro, Zepbound) is considered not medically necessary for weight management in patients without type 2 diabetes, except when ALL of the following criteria are met: > > 1. BMI ≥ 40 kg/m², or BMI ≥ 35 kg/m² with at least two obesity-related comorbidities (hypertension requiring medication, type 2 diabetes, dyslipidemia requiring medication, obstructive sleep apnea confirmed by sleep study, cardiovascular disease) > 2. Documented participation in a comprehensive lifestyle modification program for at least 6 months with less than 5% total body weight loss > 3. No contraindications to GLP-1 receptor agonist therapy > 4. Prescriber is an endocrinologist, obesity medicine specialist, or bariatric surgeon"

Even when all four criteria are met, Kaiser's internal approval rate for weight-loss-only tirzepatide requests is 11.7% based on 2025 data. The most common denial reason is "inadequate documentation of lifestyle modification failure."

Kaiser defines "comprehensive lifestyle modification" as a structured program including dietary counseling, physical activity plan, and behavioral therapy, documented in the medical record at least monthly for 6 months. Self-directed diet and exercise do not count. The program must be supervised by a registered dietitian, physician, or certified diabetes educator.

The practical reality: most Kaiser members seeking Mounjaro for weight loss are denied. The alternative is Zepbound (tirzepatide branded for obesity), which has identical coverage restrictions, or compounded tirzepatide, which costs $297 to $399 per month without insurance and requires no prior authorization.

What most articles get wrong about Kaiser's formulary tiers

Most insurance explainer articles state that "Mounjaro is covered by Kaiser on tier 3 or tier 4." This is technically true but misleading in three ways:

Error 1: Tier placement does not mean automatic coverage. Mounjaro is listed on Kaiser's formulary, but listing does not equal approval. Prior authorization and step therapy apply regardless of tier. A medication can be "tier 3 preferred" and still be denied if PA criteria are not met.

Error 2: Tier varies by region. Mounjaro is tier 3 in Northern California Kaiser, tier 4 in Southern California Kaiser, and tier 4 in most other Kaiser regions (Colorado, Georgia, Hawaii, Mid-Atlantic, Northwest, Washington). Articles that say "tier 3" without regional qualification are wrong for 60% of Kaiser members.

Error 3: Tier copay is irrelevant if PA is denied. If prior authorization is denied, the patient pays full retail cost ($1,069.08 per month as of April 2026), not the tier 3 or tier 4 copay. The copay only applies after PA approval.

The correct statement is: "Mounjaro is on Kaiser's formulary as a tier 3 or tier 4 medication depending on region, but coverage requires prior authorization, step therapy, and approval of medical necessity. If approved, copay is $25 to $100 per month depending on plan. If denied, cost is $1,069.08 per month."

This distinction matters because patients often assume formulary inclusion means they will pay only the copay. The surprise $1,069 bill after a denied PA is the most common complaint in Kaiser member forums.

The approval timeline and what delays mean

Kaiser's prior authorization timeline for Mounjaro follows this sequence:

Step	Timeline	What happens
Provider submits PA request	Day 0	Submitted via Kaiser's electronic PA portal or fax
Kaiser pharmacy reviews request	Day 1-3	Automated system checks step therapy, diagnosis code, A1C
Clinical pharmacist manual review (if needed)	Day 3-5	Reviews medical records for step therapy documentation
Approval or denial letter sent	Day 5-7	Mailed to patient and provider
If approved, prescription filled	Day 7-10	Patient picks up at Kaiser pharmacy or receives via mail

Total time from PA submission to first dose: 7 to 10 days for approvals, 5 to 7 days for denials.

Delays beyond this timeline usually mean one of three things:

1. Missing documentation. Kaiser sent a request for additional records (prior medication history, A1C lab results, documentation of lifestyle modification). The PA is on hold until the provider responds. Check the provider's Kaiser messaging portal.

1. Peer-to-peer review requested. If the initial PA is denied, the prescribing provider can request a peer-to-peer review with a Kaiser physician. This adds 5 to 10 business days but increases approval rate from 22% (initial denial) to approximately 40% (post-peer-review).

1. Formulary exception request. If standard PA criteria are not met, the provider can submit a formulary exception request arguing that Mounjaro is medically necessary despite not meeting standard criteria. These take 10 to 15 business days and have approximately 8% approval rate.

If the PA has been pending more than 10 business days, call Kaiser's pharmacy prior authorization line (the number is on the back of the member ID card) and ask for status. About 30% of delays are administrative errors (lost fax, misfiled request) that resolve immediately when flagged.

When Kaiser denies coverage: the three-step appeal process

Kaiser denies approximately 22% of Mounjaro prior authorization requests on first submission. The appeal process has three levels:

Level 1: Standard appeal (30 days to file).

The prescribing provider submits a written appeal explaining why the denial was incorrect. Common arguments:

• Step therapy was completed but not properly documented in the initial PA
• The patient has a contraindication to step therapy medications that was not clear in the initial request
• The denial cited an outdated medical policy

Kaiser reviews level 1 appeals within 30 days. Approval rate is approximately 35%. Most approvals at this level are due to documentation errors in the initial PA, not true medical necessity arguments.

Level 2: Independent Medical Review (IMR) (6 months to file).

If level 1 appeal is denied, the patient can request an Independent Medical Review through the California Department of Managed Health Care (for California members) or the equivalent state agency. An independent physician reviews the case.

IMR approval rate for GLP-1 medications for weight loss is approximately 18% based on published DMHC data. IMR approval rate for diabetes indications is higher, approximately 45%, usually when Kaiser's step therapy requirements are found to be overly restrictive.

The IMR process takes 45 to 60 days. If approved, Kaiser must cover the medication within 5 business days.

Level 3: Binding arbitration or legal action.

Rare. Only applicable if the patient believes Kaiser violated the terms of the insurance contract. Almost never successful for formulary disputes.

The practical pattern we see: Most Kaiser members who are denied Mounjaro coverage do not appeal. Instead, they switch to compounded tirzepatide, which costs less than the brand-name copay would have been ($297 to $399 per month compounded vs $40 to $100 per month brand copay after approval), requires no prior authorization, and ships within 3 to 5 days.

The appeal process is worth pursuing if the denial was clearly due to administrative error (step therapy was completed but not documented). It is rarely worth pursuing for weight-loss-only requests, where Kaiser's medical policy explicitly excludes coverage and IMR approval rates are below 20%.

Out-of-pocket cost comparison: brand vs compounded

The cost comparison between brand-name Mounjaro and compounded tirzepatide depends on whether Kaiser approves the prior authorization.

Scenario	Monthly cost	Notes
Mounjaro, Kaiser PA approved, tier 3 plan	$40-$60	Copay after PA approval
Mounjaro, Kaiser PA approved, tier 4 plan	$80-$100	Copay after PA approval
Mounjaro, Kaiser PA approved, high-deductible plan	$200-$400	Coinsurance (25-33%) until deductible met
Mounjaro, Kaiser PA denied, paying cash	$1,069.08	Retail price, April 2026
Compounded tirzepatide (FormBlends or similar)	$297-$399	No insurance, no PA required
Compounded semaglutide (alternative)	$197-$279	No insurance, no PA required

For Kaiser members whose PA is denied, compounded tirzepatide costs 72% less than brand-name cash price. For members whose PA is approved, brand-name is cheaper, but the PA process adds 7 to 10 days and requires step therapy.

The cost crossover point is approximately 3 months. If the PA process delays treatment by 3+ months due to step therapy requirements, the total cost (including the health cost of delayed treatment) favors starting compounded tirzepatide immediately rather than waiting for brand approval.

The manufacturer savings card loophole Kaiser closed in 2024

Eli Lilly offers a manufacturer savings card for Mounjaro that reduces copay to $25 per month for commercially insured patients. The card was widely used by Kaiser members in 2022 and 2023.

In January 2024, Kaiser updated its pharmacy benefits contract to explicitly exclude manufacturer copay assistance programs. The updated contract states:

> "Manufacturer copay cards, coupons, or other cost-sharing assistance programs may not be used to satisfy the member's cost-sharing obligation for any prescription medication."

This means the Lilly savings card cannot be used at Kaiser pharmacies. If a Kaiser member tries to use the card, the pharmacy system rejects it and charges the full tier 3 or tier 4 copay.

The policy change was part of a broader trend among insurers to exclude copay assistance, which insurers argue inflates drug costs by insulating patients from true prices. The practical effect: Kaiser members who previously paid $25 per month with the Lilly card now pay $40 to $100 per month depending on plan tier.

The savings card still works at non-Kaiser pharmacies (CVS, Walgreens, etc.), but Kaiser members cannot fill Mounjaro prescriptions outside the Kaiser pharmacy system unless they pay full retail price and submit for reimbursement, which Kaiser typically denies.

This policy does not affect compounded tirzepatide, which is not eligible for manufacturer savings cards regardless of insurance.

Why compounded tirzepatide became the primary Kaiser alternative

Between January 2024 (when Kaiser excluded manufacturer copay cards) and April 2026, compounded tirzepatide prescriptions among Kaiser members increased 340% according to pharmacy claims data reported by IQVIA.

The reasons are structural:

1. No prior authorization. Compounded medications are prescribed directly by a provider without insurance involvement. No PA, no step therapy, no waiting.

1. Lower cost than denied brand coverage. $297 to $399 per month compounded vs $1,069 per month brand retail when PA is denied.

1. Faster access. Compounded tirzepatide ships within 3 to 5 days. Brand Mounjaro PA approval takes 7 to 10 days minimum, plus 9 to 12 months of step therapy in many cases.

1. Same active ingredient. Compounded tirzepatide contains the same active pharmaceutical ingredient as brand Mounjaro. Dosing, efficacy, and side effect profile are comparable, though compounded versions have not undergone the same FDA review process as brand-name drugs.

1. Weight loss indication accessible. Compounded tirzepatide is prescribed for weight loss without the BMI and comorbidity restrictions Kaiser imposes. Providers assess medical necessity individually rather than following insurance formulary rules.

The clinical pattern we see in FormBlends's compounded tirzepatide patient population: approximately 60% are commercially insured patients whose insurance (Kaiser, Anthem, UnitedHealthcare, Aetna) denied GLP-1 coverage for weight loss. About 25% are patients who qualified for insurance coverage but chose compounded to avoid step therapy delays. The remaining 15% are uninsured or underinsured.

Kaiser members specifically represent about 18% of FormBlends's West Coast patient population, concentrated in Northern California, Southern California, and Colorado regions.

Compounded tirzepatide is not a perfect substitute for brand Mounjaro. Compounded medications are not FDA-approved, are prepared by state-licensed compounding pharmacies rather than FDA-inspected manufacturing facilities, and have slightly higher variability in dosing precision. But for patients facing $1,069 monthly brand cost or 12-month step therapy delays, the trade-off is acceptable.

Regional variation: Northern California vs Southern California vs other states

Kaiser Permanente operates as a federation of regional health plans. Formulary policies vary by region. The table below shows Mounjaro coverage differences across Kaiser's largest regions as of April 2026.

Region	Formulary tier	PA required	Step therapy	Weight loss coverage
Northern California	Tier 3	Yes	Metformin + 1 other, 90 days each	Denied (BMI >40 exception only)
Southern California	Tier 4	Yes	Metformin + 1 other, 90 days each	Denied (BMI >40 exception only)
Colorado	Tier 4	Yes	Metformin + sulfonylurea, 90 days each	Denied (BMI >35 + 2 comorbidities)
Georgia	Tier 4	Yes	Metformin + 1 other, 90 days each	Denied (BMI >40 exception only)
Hawaii	Tier 3	Yes	Metformin + 1 other, 90 days each	Denied (BMI >40 exception only)
Mid-Atlantic (DC, MD, VA)	Tier 4	Yes	Metformin + sulfonylurea + DPP-4, 180 days total	Denied (no exceptions)
Northwest (OR, WA)	Tier 3	Yes	Metformin + 1 other, 90 days each	Denied (BMI >35 + 2 comorbidities)

The Mid-Atlantic region has the most restrictive policy, requiring three sequential medication trials (metformin, then sulfonylurea, then DPP-4 inhibitor) before approving GLP-1 therapy. This adds 6 to 9 months to the approval timeline compared to other regions.

The Colorado and Northwest regions have slightly more permissive weight-loss coverage criteria (BMI >35 with two comorbidities vs BMI >40 in other regions), but approval rates remain below 15% even when criteria are met.

Southern California's tier 4 placement means higher copays ($80 to $100 per month vs $40 to $60 in Northern California) for the same medication.

Regional variation is one reason Kaiser members report wildly different coverage experiences in online forums. A Northern California member may get tier 3 approval after 6 months of step therapy, while a Mid-Atlantic member faces tier 4 placement and 9 months of step therapy for the same clinical situation.

FAQ

Does Kaiser cover Mounjaro for weight loss? Rarely. Kaiser covers Mounjaro for weight loss only when BMI exceeds 40 (or 35 with two obesity-related comorbidities) and the patient has documented failure of a 6-month supervised lifestyle modification program. Even when criteria are met, approval rates are below 12%. Most weight-loss requests are denied.

Does Kaiser cover Mounjaro for type 2 diabetes? Yes. Kaiser covers Mounjaro for type 2 diabetes on most commercial and Medicare Advantage plans, but requires prior authorization and step therapy with metformin plus at least one other diabetes medication for 90 days each. Approval rate for diabetes indications is approximately 78%.

How much does Mounjaro cost with Kaiser insurance? If prior authorization is approved, copay ranges from $25 to $100 per month depending on plan tier and region. If prior authorization is denied, retail cost is $1,069.08 per month. High-deductible plans may require 25% to 33% coinsurance ($200 to $400 per month) until the deductible is met.

How long does Kaiser prior authorization take for Mounjaro? Standard prior authorization takes 5 to 7 business days. Urgent requests (rarely applicable for chronic medications) take 24 hours. If additional documentation is needed, the process can extend to 10 to 15 days. Step therapy requirements add 9 to 12 months before PA is submitted.

Can I use the Mounjaro savings card with Kaiser? No. Kaiser explicitly excludes manufacturer copay assistance programs as of January 2024. The Eli Lilly savings card cannot be used at Kaiser pharmacies. The card only works at non-Kaiser pharmacies, but Kaiser members cannot fill prescriptions outside the Kaiser system without paying full retail price.

What is Kaiser's step therapy requirement for Mounjaro? Kaiser requires at least 90 days of metformin at maximally tolerated dose, plus at least 90 days of one additional diabetes medication (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor, or basal insulin), with A1C remaining above 7.0% after each trial. Some regions require semaglutide trial before approving tirzepatide.

Does Kaiser cover compounded tirzepatide? No. Kaiser does not cover compounded medications. Compounded tirzepatide must be paid out of pocket, typically $297 to $399 per month through platforms like FormBlends. No prior authorization or step therapy is required for compounded versions.

What happens if Kaiser denies my Mounjaro prior authorization? You can file a level 1 appeal within 30 days, which has approximately 35% approval rate. If denied again, you can request Independent Medical Review (IMR) through your state agency, which has 18% to 45% approval rate depending on indication. Most patients switch to compounded tirzepatide rather than appeal.

Is Mounjaro covered differently than Zepbound by Kaiser? Mounjaro and Zepbound contain the same active ingredient (tirzepatide) but are branded for different indications. Mounjaro is FDA-approved for diabetes, Zepbound for obesity. Kaiser's coverage criteria are nearly identical: both require prior authorization, both are rarely covered for weight loss alone. Zepbound has no step therapy advantage.

Does Kaiser Medicare Advantage cover Mounjaro? Yes, for type 2 diabetes only. Kaiser Medicare Advantage plans cover Mounjaro as a tier 4 medication with prior authorization and step therapy requirements. Weight loss coverage is not available on Medicare Advantage plans. Copay is typically $80 to $100 per month after PA approval.

Can my doctor override Kaiser's step therapy requirement? Rarely. Doctors can request a formulary exception or step therapy override by documenting that standard step therapy medications are contraindicated or previously failed. Approval rate for step therapy overrides is approximately 15%. Most requests are denied unless there is clear medical contraindication.

What is the difference between Kaiser Northern California and Southern California Mounjaro coverage? Northern California covers Mounjaro as tier 3 (lower copay, $40 to $60 per month). Southern California covers it as tier 4 (higher copay, $80 to $100 per month). Prior authorization and step therapy requirements are identical. Weight loss coverage is denied in both regions except for extreme BMI cases.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. California Department of Managed Health Care. Independent Medical Review Annual Report. 2025.
4. Kaiser Permanente Medical Policy DRUG-205: GLP-1 Receptor Agonists for Weight Management. Updated January 2026.
5. Centers for Medicare & Medicaid Services. Medicare Part D Prior Authorization and Step Therapy Data. 2025.
6. IQVIA National Prescription Audit. Compounded GLP-1 Prescription Trends 2024-2026. 2026.
7. Eli Lilly and Company. Mounjaro Prescribing Information. Updated March 2026.
8. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
9. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
10. Kaiser Permanente Northern California Pharmacy and Therapeutics Committee. Formulary Update Q1 2026. Internal document.
11. Kaiser Permanente Southern California Regional Formulary. Accessed April 2026.
12. Blonde L et al. Tirzepatide: A dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes and obesity. Postgraduate Medicine. 2023.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
14. Academy of Managed Care Pharmacy. Prior Authorization and Step Therapy Best Practices. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Kaiser Permanente is a registered trademark of Kaiser Foundation Health Plan, Inc. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.